Skip to main content
Accueil
  • fr
  • en

Main navigation

  • Company
    • Company profile
    • Management
      • Leadership Team
      • Board of Directors
      • Strategic Advisory Board
    • Our history
  • Science
    • Scientific approach
    • Antibody formats
    • Publications
  • Products
    • Pipeline overview
    • ------------------
    • Lacutamab
    • IPH4502
    • Monalizumab
    • Other Clinical Stage Assets
      • IPH6501
      • IPH6101
      • IPH6401
      • IPH5201
      • IPH5301
  • Partnering
  • Investors
    • Overview
    • News
    • Events
    • Stock Info
      • Share Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financial and Regulatory Information
      • Financial Reports
      • SEC Filings
      • Articles of Association
      • Number of Shares and Voting Rights
      • Share Repurchase Liquidity Agreement
      • Prospectus Related to Public Offering
      • Appraiser Reports
      • Regulated Agreements
    • General Shareholders Meeting
    • Governance
      • Corporate Governance
      • Management Team
    • Resources
      • Investor Email Alerts
  • Media
    • Media hub
    • All press releases
    • Media center
  • Careers
Menu
  1. Home

Innate Pharma to Hold its Annual General Meeting of Shareholders on May 28, 2021

April 21, 2021
The Annual General Meeting will be broadcasted live by the Company Shareholders are invited to vote at the General Meeting either by mail or by proxy Innate Pharma SA (Euronext Paris: IPH – ISIN...

Number of Shares and Voting Rights of Innate Pharma as of April 1, 2021

April 19, 2021
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “ AMF ”) General Regulation...

Innate Pharma reports Full Year 2020 financial results and business update

March 18, 2021
• Lacutamab received PRIME designation from the European Medicines Agency in Sezary Syndrome; clinical development program advances in mycosis fungoides and peripheral T-cell lymphoma • Company’s...

Innate Pharma announces conference call and webcast for Full Year 2020 financial results

March 16, 2021
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that the Company will hold a conference call on Thursday, March 18, 2021 at 2...

Number of shares and voting rights of Innate Pharma as of February 1, 2021

February 24, 2021
Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation...

10th Annual SVB Leerink Global Healthcare Conference

February 24, 2021 - February 26, 2021

Innate Pharma to participate in the 10th annual SVB Leerink Global Healthcare Conference

February 17, 2021
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the...

Innate Pharma advances lacutamab clinical development program

February 9, 2021
TELLOMAK trial progresses as cohort 2 of KIR3DL2-expressing mycosis fungoides patients advances to Stage 2 earlier than anticipated Company to initiate two new clinical trials to investigate lacutamab...

Innate Pharma to host key opinion leader discussion on the potential role of lacutamab across T-cell lymphomas

February 3, 2021
Virtual event to take place at 2:00 p.m. CET / 8:00 a.m. ET on Tuesday, February 9, 2021 Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today...
Vivier et al, 2021. Tumor-Infiltrating Natural Killer Cells Cancer discovery

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 22
  • Page 23
  • Page 24
  • Page 25
  • Current page 26
  • Page 27
  • Page 28
  • Page 29
  • Page 30
  • …
  • Next page Next ›
  • Last page Last »

Footer

  • Contact
  • Location
  • Site map
  • Legal Info
  • Terms of use
  • Privacy Notice
  • Cookies notice
  • General Conditions of Purchase

Follow us

   

Stay in touch

 Subscribe to our newsletter

 Contact us
 

Location

117, Avenue de Luminy - BP 30191
13 009 Marseille FRANCE

 +33 (0)4 30 30 30 30

 Innate Pharma, Inc.
2273 Research Boulevard, Suite 350
Rockville, MD 20850, USA

Innate Pharma
  • Company
    • Company profile
    • Management
      • Leadership Team
      • Board of Directors
      • Strategic Advisory Board
    • Our history
  • Science
    • Scientific approach
    • Antibody formats
    • Publications
  • Products
    • Pipeline overview
    • ------------------
    • Lacutamab
    • IPH4502
    • Monalizumab
    • Other Clinical Stage Assets
      • IPH6501
      • IPH6101
      • IPH6401
      • IPH5201
      • IPH5301
  • Partnering
  • Investors
    • Overview
    • News
    • Events
    • Stock Info
      • Share Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Financial and Regulatory Information
      • Financial Reports
      • SEC Filings
      • Articles of Association
      • Number of Shares and Voting Rights
      • Share Repurchase Liquidity Agreement
      • Prospectus Related to Public Offering
      • Appraiser Reports
      • Regulated Agreements
    • General Shareholders Meeting
    • Governance
      • Corporate Governance
      • Management Team
    • Resources
      • Investor Email Alerts
  • Media
    • Media hub
    • All press releases
    • Media center
  • Careers